tbuckley/cabot-search huggingface dataset:
Disease Status Is the Major Prognosis Factor for Allogenic Transplantation Outcome for Hodgkin Lymphoma: a Retrospective Study From the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)
Authors: Ambroise Marcais, Karin Bilger, Raphael Porcher, Marie Robin, Mohamad Mohty, Mauricette Michalet, Didier Blaise, Stephane Vigouroux, Pierre Bordigoni, Patrice Ceballos, Eric Deconinck, Nathalie Dehdin, Bernard Rio, Jacques-Olivier Bay, Cécile Pautas, Frederic Garban, Norbert Ifrah, Felipe Suarez, Gaelle Guillerm, Nathalie Contentin, Jean-Henri Bourhis, Marc Bernard, Jérôme Cornillon, Anne Huynh, Ibrahim yakoub Agha, Anne Sirvent, Loic Fouillard, Agnes Buzyn
Journal: Blood (2010)
Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Bleeding Complications Following Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Benjamin Brenner, Markus Pihusch, Andrea Bacigalupo, Jeff Szer, Mario von Depka Prondzinski, Bettina Gaspar-Blaudschun, Liselotte Hyveled
Journal: Blood (2004)
Risk Factors for Predicting CMV Infection in Allogeneic-PBSCT Setting: MNC Dose, Campath Use, and Acute GVHD Grade ≥II.
Authors: Byung Min Ahn, Joon Ho Moon, Yoon Young Cho, Yee Soo Chae, Jong Gwang Kim, Sang Kyun Sohn
Journal: Blood (2006)
Efficacy and Safety of Conditioning Treatment Using Bendamustine in Autologous Hematopoietic Cell Transplantation in Heavily Pretreated Patient with Lymphoma
Authors: Malgorzata Krawczyk-Kulis, Anna Kopinska, Iwona Grygoruk-Wisniowska, Slawomira Kyrcz-Krzemien
Journal: Blood (2012)
The current conceptualization of negative symptoms in schizophrenia
Authors: Stephen R. Marder, Silvana Galderisi
Journal: World Psychiatry (2017)

Negative symptoms have long been conceptualized as a core aspect of schizophrenia. They play a key role in the functional outcome of the disorder, and their management represents a significant unmet need. Improvements in definition, characterization, assessment instruments and experimental models are needed in order to foster research aimed at developing effective interventions. A consensus has recently been reached on the following aspects: a) five constructs should be considered as negative symptoms, i.e. blunted affect, alogia, anhedonia, asociality and avolition; b) for each construct, symptoms due to identifiable factors, such as medication effects, psychotic symptoms or depression, should be distinguished from those regarded as primary; c) the five constructs cluster in two factors, one including blunted affect and alogia and the other consisting of anhedonia, avolition and asociality. In this paper, for each construct, we report the current definition; highlight differences among the main assessment instruments; illustrate quantitative measures, if available, and their relationship with the evaluations based on rating scales; and describe correlates as well as experimental models. We conclude that: a) the assessment of the negative symptom dimension has recently improved, but even current expert consensus-based instruments diverge on several aspects; b) the use of objective measures might contribute to overcome uncertainties about the reliability of rating scales, but these measures require further investigation and validation; c) the boundaries with other illness components, in particular neurocognition and social cognition, are not well defined; and d) without further reducing the heterogeneity within the negative symptom dimension, attempts to develop successful interventions are likely to lead to great efforts paid back by small rewards.
Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection
Authors: Hannah C. Watkins, C. Garrett Rappazzo, Jaclyn S. Higgins, Xiangjie Sun, Nicole Brock, Annie Chau, Aditya Misra, Joseph P.B. Cannizzo, Michael R. King, Taronna R. Maines, Cynthia A. Leifer, Gary R. Whittaker, Matthew P. DeLisa, David Putnam
Journal: Molecular Therapy (2017)
Health and Health Care Use Among Individuals at Risk to Lose Health Insurance With Repeal of the Affordable Care Act
Authors: Pinar Karaca-Mandic, Anupam B. Jena, Joseph S. Ross
Journal: JAMA Internal Medicine (2017)

This study uses the Integrated Health Interview Series of the 2015 National Health Interview Survey to assess the health and health care use by individuals at risk of losing of losing health insurance with repeal of the Affordable Care Act.
THE PHENOTYPE OF TFR2-TMPRSS6 DOUBLE KNOCK OUT MICE ONLY PARTIALLYOVERLAPS THAT OF TMPRSS6 NULL MICE
Authors: Maria Pellegrino Rosa, Nai Antonella, Boero Martina, Rausa Marco, De Gobbi Marco, Saglio Giuseppe, Silvestri Laura, Roetto Antonella, Camaschella Clara
Journal: American Journal of Hematology (2013)
TCT-38 Three-year clinical data of the BIOSOLVE-I Study with the paclitaxel-eluting bioabsorbable magnesium scaffold (DREAMS) and multi-modality imaging analysis
Authors: Michael Haude, Raimund Erbel, Paul Erne, Stefan Verheye, Paul Vermeersch, Hubertus Degen, Dirk Boese, Ron Waksman, Neil Weissman, Francesco Prati, Jacques Koolen
Journal: Journal of the American College of Cardiology (2013)
Is It Relevant to Determine Routinely Levels of Circulating NK and NK Like Cells in Myelodyplastic Syndroms?.
Authors: Marie-Pierre Gourin, Franck Trimoreau, Nathalie Gachard, Jean-Luc Faucher, Julie Abraham, Natalya Dmytruk, Stephane Moreau, François Lamarche, Stéphane Girault, Pascal Turlure, Jean Feuillard, Dominique Bordessoule
Journal: Blood (2009)
Co-Treatment with Panobinostat Enhances Bortezomib-Induced Unfolded Protein Response, Endoplasmic Reticulum Stress and Apoptosis of Human Mantle Cell Lymphoma Cells
Authors: Rekha Rao, Warren Fiskus, Yonghua Yang, Rajeshree Joshi, Pravina Fernandez, Pearl Lee, Anand Jillella, Jianguo Tao, Peter Atadja, Eduardo Sotomayor, Kapil N. Bhalla
Journal: Blood (2008)
Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells
Authors: Seiichi Okabe, Tetsuzo Tauchi, Seiichiro Katagiri, Yuko Tanaka, Kazuma Ohyashiki
Journal: Blood (2012)
Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC).
Authors: Michael Roger Harrison, Daniel J. George, Mark S. Walker, Lori L. Hudson, Connie Chen, Beata Korytowsky, Edward J. Stepanski, Amy P. Abernethy
Journal: Journal of Clinical Oncology (2012)

406 Background: Targeted therapies have expanded treatment options for mRCC. Using a joint community/academic center database, we determined outcomes for “real world” mRCC patients (pts) in order to understand current treatment patterns and their effectiveness. Methods: A retrospective cohort dataset included all identified adult mRCC pts receiving care in Duke University Health System and 11 community oncology practices, diagnosed and alive since Jan. 2007, and not enrolled in a trial. Standardized chart abstraction supplemented the electronic medical record. Demographics, comorbidities, tumor characteristics, treatment patterns and outcomes were recorded. Pts were grouped by exposure sequence (TKI [sorafenib, sunitinib or pazopanib], mTOR [temsirolimus or everolimus], TKI/mTOR, etc.) for 9 sequences. Outcomes analysis for overall survival (OS) included Cox regression. Results: The cohort included 385 pts, 64 yrs old (±10.1), 66% male, 72% Caucasian; 64% had clear cell histology (25% unknown). Median OS was: mTOR (N=33; 5.4 mo), mTOR/TKI (N=11; 9.3 mo), TKI/mTOR (N=33; 13.7 mo), TKI (N=108; 21.1 mo), TKI/mTOR/TKI (N=18; 29.8 mo), TKI/TKI/mTOR (N=11; 33.1 mo), Other (N=40; 38.2 mo), TKI/TKI (N=32; 42.9 mo), No Therapy (N=99; not reached). “Other” pts received a combination or a non-TKI, non-mTOR monotherapy in the 1st three exposures. “No Therapy” pts had received no systemic therapy as of data analysis; most were alive and censored. Pts in the mTOR only sequence had trends toward worse disease at baseline with more metastatic sites (median 2.0; p=.067) and impaired performance status (18%; p=NS). When significant covariates were controlled, OS (vs. No Therapy) was poorest for pts receiving mTOR only (Hazard Ratio[HR]=2.3) and best for pts receiving TKI/TKI (HR=0.50). Significant risks were evident with liver metastasis (HR=1.7) and impaired performance status (HR=3.1). Conclusions: In the real world setting pts receiving mTOR as the 1st treatment exposure had worse OS, likely because pts with more aggressive disease were preferentially treated with mTOR. Outcomes were consistent with contemporary trials; however, several sequences (e.g. TKI/TKI, No Therapy) had surprisingly long OS, which requires further evaluation.
Prognostic Impact of Chromosomal Variation in Patients with Acute Promyelocytic Leukemia (APL); Analysis of 775 Cases Enrolled in the Japan Adult Leukemia Study Group APL Studies
Authors: Miwa Adachi, Akihiro Takeshita, Tomohiko Taki, Shigeki Ohtake, Katsuji Shinagawa, Hitoshi Kiyoi, Mitsuhiro Matsuda, Masatomo Takahashi, Nobuhiko Emi, Yukio Kobayashi, Koichi Miyamura, Hiroyuki Fujita, Toru Sakura, Masako Iwanaga, Noriko Usui, Shuichi Miyawaki, Norio Asou, Kazunori Ohnishi, Yasushi Miyazaki, Tomoki Naoe
Journal: Blood (2014)
Incidence, Risk Factors and Outcomes of Bronchiolitis Obliterans after Allogeneic Stem Cell Transplantation.
Authors: Chiaki Nakaseko, Shinnichi Ozawa, Miki Nishimura, Miwa Sakai, Kumi Ohshima, Yoshinobu Kanda, Satoshi Takahashi, Takayuki Shimizu, Shinichiro Okamoto, Akira Yokota, Fumiaki Yoshiba, Katsumichi Fujimaki, Heiwa Kanamori, Rika Sakai, Takafumi Matsushima, Tohru Sakura, Hisashi Sakamaki
Journal: Blood (2006)
Comorbidities Indexes In Patients Treated with 5-Azacitidine Are a An Useful and Easily Applicable Tool to Refine Prognostic Evaluation
Authors: Alessandro Sanna, Laura Cannella, Antonella Gozzini, Massimo Breccia, Francesca Sassolini, Alberto Bosi, Giuliana Alimena, Valeria Santini
Journal: Blood (2010)
Genome-wide association study identiﬁes HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure
Authors: Wenting Tan, Jie Xia, Yunjie Dan, Mengying Li, Shide Lin, Xingnan Pan, Huifen Wang, Yingzi Tang, Nana Liu, Shun Tan, Ming Liu, Weiwei He, Weihua Zhang, Qing Mao, Yuming Wang, Guohong Deng
Journal: Gut (2017)

<h3>Objective</h3> Acute-on-chronic liver failure (ACLF) is an extreme condition after severe acute exacerbation of chronic hepatitis B; however, the underlying genetic factors involved in its onset and progression are currently unclear. <h3>Design</h3> We carried out a genome-wide association study among 399 HBV-related ACLFs (cases) and 401 asymptomatic HBV carriers (AsCs, as controls) without antiviral treatment. The initial findings were replicated in four independent case–control sets (a total of 901 ACLFs and 1686 AsCs). The roles of risk variants on clinical traits of ACLF were also analysed. <h3>Results</h3> Among 1300 ACLFs and 2087 AsCs, we identified rs3129859 at human leucocyte antigen (HLA) class II region (chromosome 6p21.32) associated with HBV-related ACLF (combined P<i><sub>dominant</sub></i>=2.64×10<sup>−20</sup>, OR=1.83). Analysis identiﬁed <i>HLA-DRB1*12:02</i> as the top susceptible HLA allele associated with ACLF (p=3.94×10<sup>−6</sup>, OR=2.05). The association of rs3129859 was robust in ACLF subgroups (ACLFs with liver cirrhosis, p=1.36×10<sup>−16</sup>; ACLFs without liver cirrhosis, p=1.52×10<sup>−7</sup>), and patients at low-replicative phase (p=6.36×10<sup>−11</sup>, OR=2.29) or HBV e antigen-negative chronic hepatitis B phase (p=1.51×10<sup>−14</sup>, OR=1.86). Clinical traits analysis in patients with ACLF showed that the risky rs3129859*C allele was also associated with prolonged prothrombin time, faster progression to ascites development and higher 28-day mortality. <h3>Conclusions</h3> Our genome-wide association study identified <i>HLA-DR</i> as the major locus for susceptibility to HBV-related ACLF. Our findings highlight the importance of HLA class II restricted CD4+ T-cell pathway on the immunopathogenesis of HBV-related ACLF.
F<scp>ifty</scp> Y<scp>ears of</scp> R<scp>esearch in</scp> ARDS.Is Acute Respiratory Distress Syndrome a Preventable Disease?
Authors: Hemang Yadav, B. Taylor Thompson, Ognjen Gajic
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Despite significant advances in our understanding and management of patients with acute respiratory distress syndrome (ARDS), the morbidity and mortality from ARDS remains high. Given the limited number of effective treatments for established ARDS, the strategic focus of ARDS research has shifted toward identifying patients with or at high risk of ARDS early in the course of the underlying illness, when strategies to reduce the development and progression of ARDS and associated organ failures can be systematically evaluated. In this review, we summarize the rationale, current evidence, and future directions in ARDS prevention.
Mucosal Foxp3 + Regulatory T Cells Show Significant Numerical Differences in Patients with Intestinal Graft-Versus-Host Disease Compared to Infectious Diseases of the Gut.
Authors: Kathrin Rieger, Christoph Loddenkemper, Jochen Maul, Thomas Fietz, Daniel Wolff, Harald Terpe, Beate Steiner, Erika Berg, Stefan Miehlke, Martin Bornhaeuser, Thomas Schneider, Martin Zeitz, Harald Stein, Eckhard Thiel, Lutz Uharek
Journal: Blood (2005)
Effect of bosentan on MMP-7 levels as add-on therapy in idiopathic pulmonary fibrosis. A prospective study
Authors: Katerina Samara, Evi Vassalou, Ioannis Giannarakis, Ismini Lasithiotaki, Nikolaos Tzanakis, Nikolaos Siafakas, Katerina Antoniou
Journal: European Respiratory Journal (2011)

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease lacking effective treatment. Endothelin receptor antagonists were shown to have possible beneficial effects in early stages of IPF. Recent evidence suggests that increased MMP7 levels may be indicative of disease progression.  Objectives: To determine the effects of bosentan on MMP-7 serum levels in patients with IPF.  Methods: We prospectively studied eleven IPF patients, nine males and two females, aged 68.9±8.8 years. Five were current or ex-smokers (43±23.5 pack/years), the remaining non-smokers. All patients received oral bosentan 62.5 mg twice daily for 4 weeks, increased to 125 mg twice daily thereafter, for 6 months or longer, as add-on therapy to 10mgr prednisolone, acetylcysteine (600 mg tid) and Azathioprine (150 mg/day). Serum MMP-7 levels were measured using commercial ELISA kits. All the patients had routine laboratories, PFTs and radiological (HRCT) tests, 6-minute walking distance (6MWD) and alveolar-arterial gradient of oxygen tension (PA-aO2) measured at baseline, three and six months of treatment.  Results: Serum MMP-7 levels did not show any significant change from baseline (6.4±3.22 pg/ml) to three (7.39±4.77 pg/ml) and 6 months (7.61±4.76 pg/ml). There were no significant alterations in FVC, DLCO, 6MWD and PA-aO2, pre- and post-treatment. No cases of clinically significant infection, leucopenia, elevated liver enzymes or other unexpected adverse events were reported.  Conclusions: The above data suggest that bosentan as an add-on agent to standard therapy is a safe therapeutic modality which results in disease stabilization as assessed by serum MMP-7 and functional status.
Influence of Factor V G1691A or Prothrombin G20210A Mutation On Inhibitor Development in Patients with Severe Hemophilia A - an Israeli-German Database Study.
Authors: Gili Kenet, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Sven Gutsche, Susan Halimeh, Verena Janssen, Karin Kurnik, Ulrike Nowak-Gottl
Journal: Blood (2012)
One Step Nucleic Acid Amplification (OSNA) for intra-operative detection of lymph node metastases in breast cancer patients
Authors: C. Schem, N. Maass, D. O. Bauerschlag, F. Hilpert, C. Roder, T. Löning, M. Carstensen, W. Jonat, K. Tiemann
Journal: Journal of Clinical Oncology (2007)

21053 Background: Sentinel lymph node metastasis in breast cancer patients has conventionally been determined by intra- operative histopathological examination of frozen sections followed by definitive post-operative examination of permanent sections. The purpose of this study is to evaluate a more efficient method for intra-operative detection of lymph node metastasis in a clinical setting. Therefore, a new rapid method of detection of CK19 mRNA by One Step Nucleic Acid Amplification (OSNA) and Reverse Transcription Loop Mediated Isothermal Amplification (RT-LAMP) was tested against standard histological techniques. Methods: The clinical study was conducted at two facilities using 188 lymph nodes (46 patients). Lymph nodes from axillary dissected patients with breast cancer were divided into four slices. Alternate slices were used for the new method of CK19 mRNA detection (OSNA) and histopathological examination by hematoxylin &amp; eosin and cytokeratin staining. For the analysis of concordance between both methods, the slices for histopathology were cut in 4 μm sections. For the OSNA method the other 2 slices were homogenised in a short sample preparation step. Afterwards CK19 mRNA was directly amplified from the tissue lysate within 16 minutes. Results: In the clinical study, an overall concordance rate between the OSNA assay and histopathology was 92%. Several discordant results are explainable with the expected uneven distribution of metastases within the lymph nodes. Conclusions: The study indicates that OSNA is a reliable and fast diagnostic tool for the detection of lymph node metastases in breast cancer patients. This method could be beneficial to avoid diagnostic delay for the patient or second surgery based on a post-operatively diagnosed positive lymph node. No significant financial relationships to disclose.
Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials
Authors: Lorenzo Trippa, Brian Michael Alexander
Journal: Journal of Clinical Oncology (2017)

Purpose Biomarker-based clinical trials provide efficiencies during therapeutic development and form the foundation for precision medicine. These trials must generate information on both experimental therapeutics and putative predictive biomarkers in the context of varying pretrial information. We generated an efficient, flexible design that accommodates various pretrial levels of evidence supporting the predictive capacity of biomarkers while making pretrial design choices explicit. Methods We generated a randomization procedure that explicitly incorporates pretrial estimates of the predictive capacity of biomarkers. To compare the utility of this Bayesian basket (BB) design with that of a balanced randomized, biomarker agnostic (BA) design and a traditional basket (TB) design that includes only biomarker-positive patients, we iteratively simulated hypothetical multiarm clinical trials under various scenarios. Results BB was more efficient than BA while generating more information on the predictive capacity of putative biomarkers than both BA and TB. For simulations of hypothetical multiarm trials of experimental therapies and associated biomarkers of varying incident frequency, BB increased power over BA in cases when the biomarker was predictive and when the experimental therapeutic worked in all patients in a variety of scenarios. BB also generated more information about the predictive capacity of biomarkers than BA and categorically relative to TB, which generates no new biomarker information. Conclusion The BB design offers an efficient way to generate information on both experimental therapeutics and the predictive capacity of putative biomarkers. The design is flexible enough to accommodate varying levels of pretrial biomarker confidence within the same platform structure and makes clinical trial design decisions more explicit.
Physiotherapy Offers No Benefit in Treating Ankle Sprains
Authors: Anita Slomski
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract #1070: Targeting cancer stem cells and vasculatures by a novel anti-dll4 antibody inhibits pancreatic tumor growth and delays tumor recurrence
Authors: Wan-Ching Yen, Marcus Fischer, Lucia Beviglia, Pete Yeung, Yuwang Liu, Ann Kapoun, Austin Gurney, Timothy Hoey
Journal: Cancer Research (2009)

Clinical management of pancreatic cancer is very challenging and this disease remains the fourth most common cause of cancer-related deaths. It has been suggested that cancer stem cells drive tumor growth and progression and are preferentially resistant to current therapies. Delta-like 4 ligand (DLL4) is an important component of Notch-mediated stem cell self-renewal and vascular development. We hypothesized that targeting cancer stem cells and the tumor vasculature by interfering with the DLL4/Notch pathway will improve treatment outcome. We developed anti-DLL4 antibodies with potent binding and blocking activities that recognize either human or murine DLL4 to investigate the role of DLL4 in pancreatic cancer. In vivo studies using primary pancreatic xenograft tumor models showed that anti-DLL4 was efficacious as a single agent and in combination with gemcitabine against both high and low grade pancreatic tumors. Gene expression analysis showed that anti-DLL4 affected vascular-related genes in the stroma and Notch target genes in the tumor and stroma. Histologic analysis indicated that the anti-DLL4-mediated anti-tumor effects were associated with a decrease in cell proliferation and an increase in vascular density, hypoxia, apoptosis and differentiation. These effects were further enhanced by the combination treatment with gemcitabine. Furthermore, inclusion of anti-DLL4 delayed pancreatic tumor recurrence following termination of gemcitabine. A tumorigenicity study indicated that treatment with anti-DLL4 decreased cancer stem cell frequency as measured by in vivo limiting dilution assay, whereas gemcitabine alone was ineffective. The combination of anti-DLL4 and gemcitabine further decreased cancer stem cell frequency compared to single agents. Our findings provide a rationale for targeting cancer stem cells and the vasculature through interference with the DLL4/Notch pathway as a therapeutic approach in cancer treatment.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1070.
The Prognostic Impact of High MEL1 Gene Expression in Pediatric Acute Myeloid Leukemia
Authors: Norio Shiba, Kentaro Ohki, Yusuke Hara, Genki Yamato, Myoung-ja Park, Hitoshi Ichikawa, Kobayashi Tohru, Tomizawa Daisuke, Manabu Sotomatsu, Hirokazu Arakawa, Keizo Horibe, Takashi Taga, Souichi Adachi, Akio Tawa, Yasuhide Hayashi
Journal: Blood (2014)